Large-scale randomized controlled trials reveal that GLP-1 receptor agonists deliver cardiovascular risk reduction and slow kidney disease progression in high-risk individuals with type 2 diabetes, extending well beyond their established glucose control and weight loss effects. The drugs operate through multiple pathways including delayed gastric emptying, glucagon suppression, microbiome modifications, and direct hypothalamic satiety enhancement. This cardiovascular protection represents a paradigm shift in how we view these medications. Originally developed for diabetes management, GLP-1 agonists now emerge as cardioprotective agents with kidney-sparing properties, potentially reshaping treatment algorithms for metabolic disease. However, significant concerns temper this enthusiasm. The drugs cause muscle and bone mass loss alongside gastrointestinal side effects, raising questions about long-term body composition impacts in aging adults where sarcopenia and osteoporosis already pose risks. Weight regain after discontinuation and adherence challenges further complicate their therapeutic profile. The muscle and bone loss particularly warrant investigation given their implications for functional independence and fracture risk in older populations, potentially creating a trade-off between metabolic benefits and musculoskeletal health.